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Purpose: Although the data are promising from limited studies with technetium-
99m ubiquicidin (99mTc-UBI) scintigraphy in detection of infection in humans,
these studies have had a limited sample size. This study was conducted to provide
a systematic review and meta-analysis of the reported diagnostic accuracy of
99mTc-UBI scintigraphy in detection of an infectious process.
Materials and Methods: The PubMed/MEDLINE, Web of Science, EMBASE,
and Google Scholar literature databases were systematically searched to find the
relevant human studies on 99mTc-UBI scintigraphy. For each eligible study, the true-
positive, false-positive, true-negative, and false-negative findings at 99mTc-UBI
scintigraphy were recorded, and the overall statistical parameters were acquired.
Result: Ten studies carried out from 2004 to 2010 were included in the analysis.
The pooled data sensitivity was 94.5 % and with a 95% confidence interval of
91.2%Y96.8%. The pooled specificity was still as high as about 92.7%. The
range of reported specificity was from 80% to 100%. The overall accuracy was
93.7% (95% CI: 91.2%Y95.7%).
Conclusion: The study demonstrated that 99mTc-UBI scintigraphy can be used
to identify an infectious process with admirable accuracy in early views; how-
ever, further investigations are recommended.
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The prompt and timely clinical diagnosis of infection can be chal-lenging, but it is associated in a crucial way with a patient’s care
management. Current available radiopharmaceuticals are often unable
to differentiate between sterile inflammation and infection. Several
pharmaceuticals labeled with various radioisotopes, such as liposomes
labeled with technetium-99m (99mTc),1 immunoglobulins,2,3 the
avidin-biotin system,4 antigranulocyte antibodies and antibody frag-
ments, chemotactic peptides, cytokines, interleukins, platelet factor-4,
and ciprofloxacin labeled with 99mTc,5 have been applied, but an opti-
mal radiotracer has not yet been established. Therefore, autologous
leukocytes labeled with 111In or 99mTc-HMPAO are still considered
the gold standard despite their limitations.6 Consequently, the practice
of directly targeting infectious agents with radiolabeled antibiotics or
antimicrobial peptides was introduced,7 and a number of radiola-
beled peptides have been assessed.8,9 Among the several radiolabeled
peptides options, 99mTc-labeled cationic antimicrobial peptides origi-
nating from ubiquicidin (UBI) are increasingly used in the diagnostic
evaluation of patients.10,11
Although results from limited preclinical and pilot studies in
patients are promising,12,13 they had a limited sample size. So we
have performed a meta-analysis of diagnostic studies regarding
the accuracy of 99mTc-UBI 29Y41 scintigraphy in the identification
of infection.
MATERIALS AND METHODS
Identification and Eligibility of
Pertinent Investigations
An attempt was made to identify all investigations regarding
the diagnostic accuracy of ubiquicidin (UBI) labeled with 99mTc for
the detection of infection in patients.
All pertinent investigations were included, not considering
the type of UBI used and regardless of the location of disease. The
PubMed/MEDLINE, Web of Science, EMBASE, and Google Scholar
literature records were systematically searched for publications from
January 1965 up to September 2012. The search strategy was based
on the terms ‘‘99mTc-ubiquicidin scintigraphy,’’ ‘‘99mTc-UBI scin-
tigraphy,’’ ‘‘antimicrobial peptides scan using UBI,’’ ‘‘ubiquicidin
scan,’’ and ‘‘UBI scan.’’ Experimental investigations on animals were
excluded.
Data Extraction
First, 2 researchers (A.O., M.A.) obtained data from eligible in-
vestigations separately and discussed discrepancies, and when agreement
was not attained, a third researcher (M.A.) helped to resolve the differ-
ence. For each study, several itemswere recorded such as authors’ names,
publication year, number of eligible patients, inclusion and exclusion
criteria, study design (prospective, retrospective, or unclear), demo-
graphic characteristics of patients, location of disease, type of synthetic
fragments UBI (UBI 18Y35 or UBI 29Y41), methods used for the inter-
pretation of the results (qualitative or semiquantitative), and the number
of readers who interpreted the final diagnosis. The explanation of the
reference method used to document infection was noted. The quality of
evidence using the Critical Appraisal Skills Programme tool for diag-
nostic tests was also considered.14
Statistical Analysis
For each study, the number of true-positive, false-positive, true-
negative, and false-negative findings at 99mTc-UBI scintigraphy, as
compared with the standard method, was recorded in a 2 2 table. We
calculated true-positive (TP), true-negative (TN), false-positive (FP),
and false-negative (FP) values by summing up the individuals of each
category from all studies included. Then sensitivity was calculated
as TP/TP + FN and specificity as TN/TN + FP. The accuracy was also
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calculated as TP + TN/TP + TN + FP + FN. The confidence intervals
of proportions were calculated using the Exact Binomial Method.
The data analysis was carried out using STATA software, version
11 (StataCorp, College Station, TX, USA).
RESULTS
Ten studies carried out from 2004 to 2010 were included in the
analysis. The characteristics of these studies are shown in Tables 1, 2,
and 3.
Sensitivity: Six out of 10 studies reported a perfect sensitivity
for the technique. The sensitivities for others were from 40% to 97.5%.
The pooled data sensitivity was 94.5 % and with a 95% confidence
interval of 91.2%Y96.8%.
Specificity: Unlike sensitivity, the specificity is heterogeneous
among the studies; however, the pooled specificity is still as high as
about 92.7%. The range of reported specificity was from 80% to
100%, and only 2 studies reported a perfect specificity.
The values for all included studies and summary values have
been summarized in Table 3.
DISCUSSION
An infection process that includes bone, soft tissue, and or-
thopedic device infection is a critical problem that needs rapid di-
agnosis and treatment, especially with an incremental growth in
resistance to new broad-spectrum antibiotic drugs.5 The diagnosis of
an infection process is often not clear-cut, and it is associated with the
severity of bone or soft-tissue involvement as well as with the host’s
reaction to pathogenic agents.23
Nuclear medicine techniques play an important role in this
field, and several radiopharmaceuticals have been applied in the past,
such as immunoglobulins,2,3 liposomes, ciprofloxacin labeled with
99mTc,1 the avidin-biotin system,4 antigranulocyte antibodies and
antibody fragments, chemotactic peptides, cytokines, interleukins,
and platelet factor-45; nevertheless, the optimal radiopharmaceutical
has not yet been developed.
The optimal radiotracer should facilitate early diagnosis, should
result in little absorbed radiation exposure, and should enable the dif-
ferentiation of inflammation from infection.24 Safety, cheapness,
availability, and fast clearance from the blood and the body are further
characteristics of an ideal radiopharmaceutical. Moreover, it should be
simple and rapid in preparation.24 Almost all present available radio-
pharmaceuticals possess some of these criteria, but up to now, no
single radiotracer is known in clinical practice that can enable un-
doubted discrimination of infection from sterile inflammation.24
However, among all radiotracers, antimicrobial peptides that
attach directly to bacteria are preferred, relative to other radiophar-
maceuticals,16 and among all the human-derived antimicrobial pep-
tides tested, the UBI 29Y41 has demonstrated the greatest promise.
99mTc-labeled UBI 29Y41 is a small synthetic peptide (amino
acid sequence TGRAKRRMQYNRR; 1693 Da), which originated
TABLE 1. Characteristics of Participants Included in the Studies
Study Study Design Mean Age; Range, yr Men/Women Reported Disease(s)
Assadi et al,15 2011 Prospective 48.9; 20Y69 12/8 Suspicion of osteomyelitis, due to diabetic foot ulcers
inflammation at the site of prosthesis, or bone fractures
Akhtar et al,16 2005 Prospective 31.7; 5Y75 9/9 Suspected bone, soft-tissue, or prosthesis infections
Aryana et al,17 2012 Prospective 47; 20Y79 18/16 Painful total hip prosthesis
Gandomkar et al,12 2008 Prospective 55; 35Y75 5/2 Suspected bone or soft-tissue infections, osteomyelitis, cellulitis
Arteaga de Murphy et al,18 2010 Prospective 45; 18Y88 56/92 FUO, osteomyelitis, diabetic foot, prosthesis infection, septic
arthritis, bacteremia, suspected bone infection
Sepulveda-Mendez et al,13 2010 Retrospective NR NR FUO
Dillmann-Arroyo et al,19 2011 Retrospective 50; NR 15/12 Suspected vertebral osteomyelitis
Melendez-Alafort et al,20 2004 Prospective 11.2; 2Y15 4/2 Suspected bone infection
Fard-Esfahani et al,21 2010 Prospective 58; 48Y79 10/5 Suspicion of osteomyelitis due to diabetic foot
Vallejo et al,22 2008 Prospective 50; 27Y65 8/5 Suspected mediastinitis after cardiac surgery
NR indicates not reported; FUO, fever of unknown origin.
TABLE 2. Characteristics of 99mTc-UBI Scintigraphy in Included Diagnostic Studies
Study
99mTc
(MBq)
Type of Synthetic
Fragments UBI
Scanning
Time, min No. of Readers Analysis Blinding
Reference
Standard
Assadi et al,15 2011 740 29Y41 1Y15, 30, 45, 60, 120, 240 2 SQ, Q Yes C, FU, H, M, R
Akhtar et al,16 2005 370Y400 29Y41 1Y10, 30, 60, 120, 240 NR SQ, Q Yes C, M, R
Aryana et al,17 2012 740 29Y41 1Y30 2 SQ, Q Yes C, FU, H, M, R
Gandomkar et al,12 2008 555Y740 29Y41 1Y45, 30, 60, 120 NR SQ, Q Yes C, FU, M, R
Arteaga de Murphy et al,18 2010 555Y740 29Y41 30, 120, 240, 1440 2Y3 SQ, Q Yes C, R
Sepulveda-Mendez et al,13 2010 370Y740 29Y41 120, 360 2 Q Yes C, FU, M, R
Dillmann-Arroyo et al,19 2011 NR 29Y41 120 2 Q Yes C, FU, H, M, R
Melendez-Alafort et al,20 2004 74Y222 29Y41 1, 30, 120, 240, 1440 3 SQ, Q Yes H, R
Fard-Esfahani et al,21 2010 555Y740 29Y41 1Y10, 60, 120 3 Q Yes C
Vallejo et al,22 2008 740 29Y41 120 2 SQ, Q Yes C, FU
NR indicates not reported; SQ, semiquantitative; Q, qualitative; C, culture; FU, clinical follow-up; H, histologic; M, microbiologic or laboratory examination other than culture; R,
radiologic examination, including radiography, CT, MR imaging, and scintigraphy.
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from human UBI and which attaches preferentially to bacteria in vitro
and not to activated leukocytes.25 The 99mTcYUBI 29Y41 scans have
depicted the most promising results for delineation between infection
and inflammation in animal models11,26,27 and also in inadequate
human investigations.12,13,15,16,18,19,28,29
Our meta-analysis showed that 99mTcYUBI 29Y41 scans had a
reasonably high differentiation ability in recognizing an infection
among patients who had possible infection in the soft tissue, muscu-
loskeletal system, and prosthesis. The overall accuracy was 93.7%.
The 99mTcYUBI 29Y41 scan has been applied to the diagnosis
of infection in limited clinical situations such as osteomyelitis and soft-
tissue infections,15,16 spondylitis,19 fever of unknown origin,13 pros-
thesis,17 and endocarditis (which we used in limited cases); except for
diabetic patients with a poor vascular bed,21 high sensitivities and
specificities were mentioned. Systematic assessment of diagnostic
ability in these settings would be helpful to illustrate the most favorable
spectrum of applications for this scintigraphic modality.
Consequently, 99mTc UBI 29Y41, without localization in ster-
ile inflammation and with an absence of immunological side effects,
may be considered an option for leukocyte labeling, which is still
applied as the gold standard for detection of infection in nuclear
medicine. It can also be used in leukopenic patients. Furthermore, it
was demonstrated that 99mTcYUBI (29Y41) accumulation directly
represents the number of viable bacteria, and it is applicable for the
monitoring of antibiotic treatment.28,30
Furthermore, in all studies, the maximum contrast (A/N ratio)
was obtained in the earliest time postY99mTc-UBI injection.12,16 These
results may indicate a first pass-like distribution with strong avidity of
the radiotracer in the trend of its targets, resulting in the easy diagnosis
of infection as early as few minutes postinjection. In addition, 99mTc-
UBI 29Y41 scans illustrated rapid localization to the target region and
fast renal clearance, with insignificant liver uptake and hepatobiliary
excretion.12,16,20
In our meta-analysis, a number of reference standard methods
were used in the studies, including cultures and other microbiologic
examination, histopathologic examination, clinical follow-up exami-
nation, and radiologic examination in different combinations. None of
these studies is perfect as a reference standard for confirming the di-
agnosis of infection. Miscategorization bias as a result of inadequate
standard methods may have an effect on the estimation of the statistical
parameters of a tested method, which may inflate or deflate its diag-
nostic ability. Themix of some standardmethods in the studies, however,
perhaps diminished this factor.
Although this meta-analysis showed good insight into using
99mTc-UBI in the diagnosis of infection, especially in musculoskel-
etal infection, it should be mentioned that it has some limitations.
The major limitations are the relatively small sample size with
different underlying problems. The meta-analysis is much larger than
the largest eligible study and indicates the need to include more large-
scale evidence. The second limitation is the application of significant
variability in the reference standard methods in the eligible studies
and the nonperformance of statistical parameters according to the type
of reference standard used, due to the lack of provision of separate
results based on the reference standard in the eligible investigations.
Third, the dosages of 99mTc, the time of scanning post-administration
of UBI, the study designs, and the age groups varied throughout the
studies, but it is uncertain how these factors might affect the results.
Fourth, the interpretation of the 99mTcYUBI scan was based on quali-
tative or semiquantitative methods with 2 or 3 readers so that some
diagnostic biases are to be anticipated. Fifth, even though we searched
for all eligible studies, the fact that there were some missing studies
was inevitable.
On the basis of the current study, 99mTcYUBI imaging appears
to have distinct merits as a diagnostic method in the detection of in-
fection, especially in the musculoskeletal system. However, it cannot
yet fully substitute for the existing tests used for the diagnosis of in-
fection, especially in diabetic patients.
CONCLUSION
The study demonstrated that 99mTcUBI scintigraphy can be used
to identify an infectious process with 93.7% accuracy in early views;
however, further investigations are recommended.
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